Last edition
News about "KalVista Pharmaceuticals"
Chiesi Group to Acquire KalVista Pharmaceuticals to Expand Rare Disease Portfolio
Chiesi Group to acquire KalVista Pharmaceuticals for USD 1.9 billion, adding an oral on-demand therapy for hereditary angioedema and strengthening its global rare disease portfolio, with closing expected in Q3 2026.
KalVista Pharmaceuticals | 30/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members